Malignant Tumour

What happens when doctors don’t act as they should? And what's the ruling against neurosurgeon Charlie Teo?

Retrieved on: 
Thursday, July 13, 2023

After several years of controversy, and both praise and blame for his willingness to perform high-risk surgeries, neurosurgeon Charlie Teo has been subject to practice restrictions by a special committee of the Medical Council of New South Wales. So how does the process of restricting doctors’ medical practice work? And what did this mean for Teo?How are health practitioners regulated in Australia? Health practitioner regulators in Australia aren’t generally empowered to make punitive decisions about health professionals’ conduct.

Key Points: 


After several years of controversy, and both praise and blame for his willingness to perform high-risk surgeries, neurosurgeon Charlie Teo has been subject to practice restrictions by a special committee of the Medical Council of New South Wales. So how does the process of restricting doctors’ medical practice work? And what did this mean for Teo?

How are health practitioners regulated in Australia?

    • Health practitioner regulators in Australia aren’t generally empowered to make punitive decisions about health professionals’ conduct.
    • Instead, Australia’s health practitioner regulations (the so-called “national law”) require decision-makers to exercise their powers to protect patients.
    • As the Australian Health Practitioners Regulation Agency (AHPRA) acknowledges, requirements to protect the public may sometimes result in “a determination that is harsher on the practitioner than if punishment were the sole purpose”.

What happened in the Teo case?

    • In late 2022, proceedings commenced against Teo via two complaints by the New South Wales Health Care Complaints Commission (HCCC).
    • Tragically, neither patient regained consciousness after the operations and both patients died – one just ten days after.
    • The HCCC alleged Teo had engaged in two categories of this wrongdoing: conduct below the standard reasonably expected of a doctor of his training and experience, and unethical conduct.

What were the findings and consequences for Teo?

    • Though the committee is not legally bound to apply the rules of evidence applied in criminal courts, it decided, broadly for procedural fairness reasons, to receive and consider all of Teo’s unchallenged evidence.
    • In a decision of more than 100 pages, the committee found Teo guilty of unsatisfactory professional conduct.
    • Read more:
      Doctors may soon get official 'endorsements' to practise cosmetic surgery – but will that protect patients?

What about patient autonomy or clinical freedom?

    • Here, the committee had to balance the practitioner’s right to practise medicine against the paramount consideration of patient health and safety and against the patient’s right to exercise autonomy.
    • a surgeon does not have a licence to undertake any conceivable procedure even with the agreement or acquiescence of the patient.

Is medical regulation strict in Australia and NSW?

    • Many reviews and academic studies find the national law to be fair and appropriate, or not strict enough.
    • However, some scholars and representative groups including the Australian Medical Association (AMA) find some aspects are too strict and unsympathetic to practitioners.
    • But a potted history of NSW medical history showcases how successive medical scandals have tended to drive strong regulatory reform.

What next for Teo?


    Teo may appeal the orders of the committee to the NSW Civil and Administrative Tribunal or seek a review of the conditions. But as the conditions are not subject to an end date, it appears they will otherwise continue indefinitely.

    Read more:
    How can the health regulator better protect patients from sexual misconduct?

Cosmo announces territory expansion agreement for Lumeblue™ (Methylene Blue MMX™) with China Medical System Holdings

Retrieved on: 
Friday, March 31, 2023

Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansion of the license agreement for Lumeblue™ with China Medical System Holdings Limited (“CMS”) (SEHK: 867).

Key Points: 
  • Dublin, Ireland – March 30, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the territory expansion of the license agreement for Lumeblue™ with China Medical System Holdings Limited (“CMS”) (SEHK: 867).
  • The expansion goes beyond the existing licensed territories (Greater China including the mainland China, Hong Kong, Macao, and Taiwan) to include several countries belonging to the “Pan-Asia” region.
  • Reported successful phase III clinical trial of Lumeblue™ in China:
    In December 2022, Cosmo announced the successful phase III clinical trial of Lumeblue™ in China, sponsored by its partner China Medical System Holdings Limited (CMS) (867.HK).
  • We are thus very much looking forward to working together with CMS to bring Lumeblue™ in these regions”.

Insights on the Interventional Oncology Global Market to 2028 - More Efficiency and Quick Recovery Offered by Interventional Oncology is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022

The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period.

Key Points: 
  • The Global Interventional Oncology Market size is expected to reach $2.9 billion by 2028, rising at a market growth of 6.2% CAGR during the forecast period.
  • Interventional oncology (IO) is an emerging subspecialty that emphasizes on using image-guided processes (diagnostics/surgeries) to improve cancer therapy.
  • Along with surgery, medication, and radiation, IO is currently the fourth pillar of modern oncology care.
  • Because of the rising number of cancer cases among individuals around the world, the interventional oncology market is expected to rise faster in the coming years.

Global Proleukin Market Report to 2027 - Players Include Chiron and Prometheus Laboratories - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 31, 2022

The global proleukin market is anticipated to grow at a considerable CAGR during the forecast period.

Key Points: 
  • The global proleukin market is anticipated to grow at a considerable CAGR during the forecast period.
  • Some of the companies operating in the global proleukin market include Chiron Corp., Prometheus Laboratories, and others.
  • Analysis of regional regulations and other government policies impacting the global proleukin market.
  • Insights about market determinants that are stimulating the global proleukin market.

Global Interventional Pulmonology Market Research Report 2021: Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 8, 2022

The "Interventional Pulmonology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Interventional Pulmonology Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029" report has been added to ResearchAndMarkets.com's offering.
  • The interventional pulmonology market is set to grow at a compounded annual growth rate (CAGR) of 4.8% during the forecast period from 2021 to 2029.
  • Stringent norms related to early diagnosis and medical intervention drive the interventional pulmonology market growth in European region.
  • Supportive regulatory environment provided by regional healthcare bodies further bolster the market growth in Asia Pacific region.